Investigating the Effect of Zinc Supplementation on Probability of Relapse and Mental Health in Patients with Opioid Use Disorder Undergoing Methadone Maintenance Treatment

Overview

Journal Subst Abuse Treat Prev Policy

Publisher Biomed Central

Specialty Psychiatry

Date 2023 Jan 7

PMID 36609286

Authors

Zahra Amini

Ebrahim HeidariFarsani

Affiliations

Soon will be listed here.

Abstract

Background: Considering different factors, such as high withdrawal rates in methadone maintenance treatment (MMT) programs alongside mental health (MH) problems appearing in patients with opioid use disorder and the lack of prior research on the effect of zinc supplementation in this respect, the present study aimed to investigate the effect of zinc supplementation on the probability of relapse (PoR) and MH problems in patients with opioid use disorder undergoing MMT.

Methods: For this purpose, a randomized controlled trial with a clinical basis was fulfilled on a total of 68 patients with opioid use disorder receiving MMT, allocated to two groups, viz. intervention, and control (each one consisting of 34 individuals). Then, the participants in the intervention group were given zinc supplements combined with methadone for three months, and the controls only took methadone, according to the treatment plan. The data were collected using the Relapse Prediction Scale (RPS) and the Depression, Anxiety, and Stress Scale 21 (DASS-21) before, one month after, and at the end of the intervention program.

Findings: Compared to the control group, the likelihood of drug use (p = 0.01), drug craving (p = 0.002), and the RPS total score (p = 0.002) in the intervention group was significantly lower. Moreover, the results revealed a significant decreasing trend in depression (p = 0.01), anxiety (p < 0.001), stress (p = 0.001), and the DASS-21 total score (p = 0.001) in the intervention. Compared to the control group, the DASS-21 total score (p < 0.001) in the intervention group was significantly lower.

Conclusion: Accordingly, it was concluded that zinc supplementation could reduce the PoR and improve MH problems in patients with opioid use disorder experiencing MMT. However, further research is recommended to fill the gaps.

Trial Registration: The research protocol has also been listed on the Iranian Registry of Clinical Trials (IRCT) with code no. IRCT2020050904736N1.

References

Liu D, Gu J, Xu H, Hao C, Jiao M, Zhang X . Club drugs and alcohol abuse predicted dropout and poor adherence among methadone maintenance treatment patients in Guangzhou, China. AIDS Care. 2016; 29(4):458-463. PMC: 7243263. DOI: 10.1080/09540121.2016.1259452. View

Wang J, Um P, Dickerman B, Liu J . Zinc, Magnesium, Selenium and Depression: A Review of the Evidence, Potential Mechanisms and Implications. Nutrients. 2018; 10(5). PMC: 5986464. DOI: 10.3390/nu10050584. View

Nakamura M, Miura A, Nagahata T, Shibata Y, Okada E, Ojima T . Low Zinc, Copper, and Manganese Intake is Associated with Depression and Anxiety Symptoms in the Japanese Working Population: Findings from the Eating Habit and Well-Being Study. Nutrients. 2019; 11(4). PMC: 6521019. DOI: 10.3390/nu11040847. View

Le T, Le M, Dang A, Dang A, Nguyen C, Pham H . Multi-level predictors of psychological problems among methadone maintenance treatment patients in difference types of settings in Vietnam. Subst Abuse Treat Prev Policy. 2019; 14(1):39. PMC: 6751619. DOI: 10.1186/s13011-019-0223-4. View

Richert T, Anderberg M, Dahlberg M . Mental health problems among young people in substance abuse treatment in Sweden. Subst Abuse Treat Prev Policy. 2020; 15(1):43. PMC: 7315521. DOI: 10.1186/s13011-020-00282-6. View

da Silva L, de Santana M, Costa P, Pereira E, Nepomuceno C, Queiroz V . Zinc supplementation combined with antidepressant drugs for treatment of patients with depression: a systematic review and meta-analysis. Nutr Rev. 2020; 79(1):1-12. DOI: 10.1093/nutrit/nuaa039. View

Wright F, Beck A, Newman C, Liese B . Cognitive therapy of substance abuse: theoretical rationale. NIDA Res Monogr. 1993; 137:123-46. View

Mathers B, Degenhardt L, Ali H, Wiessing L, Hickman M, Mattick R . HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet. 2010; 375(9719):1014-28. DOI: 10.1016/S0140-6736(10)60232-2. View

Ranjbar E, Kasaei M, Mohammad-Shirazi M, Nasrollahzadeh J, Rashidkhani B, Shams J . Effects of zinc supplementation in patients with major depression: a randomized clinical trial. Iran J Psychiatry. 2013; 8(2):73-9. PMC: 3796297. View

10.

Tantillo T, Jagtiani M, Silverman E, Bitterman A, Scuderi G . Zinc deficiency: A cause of opioid-induced physical dependence and addiction in post-operative total hip arthroplasty patients. J Opioid Manag. 2021; 17(2):145-154. DOI: 10.5055/jom.2021.0607. View

11.

Leppert W . The impact of opioid analgesics on the gastrointestinal tract function and the current management possibilities. Contemp Oncol (Pozn). 2013; 16(2):125-31. PMC: 3687404. DOI: 10.5114/wo.2012.28792. View

12.

Nabipour S, Said M, Hussain Habil M . Burden and nutritional deficiencies in opiate addiction- systematic review article. Iran J Public Health. 2015; 43(8):1022-32. PMC: 4411899. View

13.

Choi S, Liu X, Pan Z . Zinc deficiency and cellular oxidative stress: prognostic implications in cardiovascular diseases. Acta Pharmacol Sin. 2018; 39(7):1120-1132. PMC: 6289396. DOI: 10.1038/aps.2018.25. View

14.

Hagmeyer S, Haderspeck J, Grabrucker A . Behavioral impairments in animal models for zinc deficiency. Front Behav Neurosci. 2015; 8:443. PMC: 4285094. DOI: 10.3389/fnbeh.2014.00443. View

15.

Lovibond P, LOVIBOND S . The structure of negative emotional states: comparison of the Depression Anxiety Stress Scales (DASS) with the Beck Depression and Anxiety Inventories. Behav Res Ther. 1995; 33(3):335-43. DOI: 10.1016/0005-7967(94)00075-u. View

16.

Ciubotariu D, Ghiciuc C, Lupusoru C . Zinc involvement in opioid addiction and analgesia--should zinc supplementation be recommended for opioid-treated persons?. Subst Abuse Treat Prev Policy. 2015; 10:29. PMC: 4523930. DOI: 10.1186/s13011-015-0025-2. View

17.

Stewart J, Rand K, Muldoon M, Kamarck T . A prospective evaluation of the directionality of the depression-inflammation relationship. Brain Behav Immun. 2009; 23(7):936-44. PMC: 2749896. DOI: 10.1016/j.bbi.2009.04.011. View

18.

Mlyniec K, Gawel M, Doboszewska U, Starowicz G, Pytka K, Davies C . Essential elements in depression and anxiety. Part II. Pharmacol Rep. 2015; 67(2):187-94. DOI: 10.1016/j.pharep.2014.09.009. View

19.

Tejwani G, Hanissian S . Modulation of mu, delta and kappa opioid receptors in rat brain by metal ions and histidine. Neuropharmacology. 1990; 29(5):445-52. DOI: 10.1016/0028-3908(90)90166-o. View

20.

Bottesi G, Ghisi M, Altoe G, Conforti E, Melli G, Sica C . The Italian version of the Depression Anxiety Stress Scales-21: Factor structure and psychometric properties on community and clinical samples. Compr Psychiatry. 2015; 60:170-81. DOI: 10.1016/j.comppsych.2015.04.005. View